ID: ALA3401387

Max Phase: Preclinical

Molecular Formula: C33H40FN3O5

Molecular Weight: 577.70

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCC(CC)CC1(O)CCN(C(=O)Nc2cc(Oc3ccc(F)cc3)cc(Oc3ccc(C(=O)N(C)C)cc3)c2)CC1

Standard InChI:  InChI=1S/C33H40FN3O5/c1-5-23(6-2)22-33(40)15-17-37(18-16-33)32(39)35-26-19-29(21-30(20-26)42-28-13-9-25(34)10-14-28)41-27-11-7-24(8-12-27)31(38)36(3)4/h7-14,19-21,23,40H,5-6,15-18,22H2,1-4H3,(H,35,39)

Standard InChI Key:  ZUXWVQLEWURXBU-UHFFFAOYSA-N

Associated Targets(Human)

Sphingosine 1-phosphate receptor Edg-5 1593 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lysophosphatidic acid receptor Edg-2 779 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Sphingosine 1-phosphate receptor Edg-3 2543 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lysophosphatidic acid receptor Edg-4 418 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 577.70Molecular Weight (Monoisotopic): 577.2952AlogP: 7.30#Rotatable Bonds: 10
Polar Surface Area: 91.34Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.63CX Basic pKa: CX LogP: 5.51CX LogD: 5.51
Aromatic Rings: 3Heavy Atoms: 42QED Weighted: 0.26Np Likeness Score: -1.02

References

1. Kusumi K, Shinozaki K, Kanaji T, Kurata H, Naganawa A, Otsuki K, Matsushita T, Sekiguchi T, Kakuuchi A, Seko T..  (2015)  Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.,  25  (7): [PMID:25746814] [10.1016/j.bmcl.2015.02.029]
2. Luo D, Liu X, Jiang L, Guo Z, Lv Y, Tian X, Wang X, Cui S, Wan S, Qu X, Xu X, Li X..  (2022)  Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer.,  65  (21.0): [PMID:36269639] [10.1021/acs.jmedchem.2c00958]

Source